首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer
【24h】

Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer

机译:非小细胞肺癌中腺和鳞状细胞标志物的共定位

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Accurate classification of lung carcinomas is crucial for selecting appropriate and adequate chemotherapy treatment. In this study, glandular (adenocarcinoma), and squamous cell differentiation were examined in non-small cell lung carcinoma (NSCLC) without obvious light-microscopic signs of squamous and glandular differentiation. Materials and Methods: All lung tumours diagnosed as NSCLC (n=61), without obvious squamous or glandular features, were obtained by bronchial biopsy or core biopsy supported by computed tomography. They were diagnosed during 1996-2009, at the Department of Pathology, Gavle Hospital, Sweden. The tumours were examined immunohistochemically with antibodies against CK5/6, p63 (squamous cell markers) and carcinoembryonic antigen (CEA) (adenocarcinoma cell marker). Double immunostaining (p63/CEA) was also performed on individual tumours. Results: The tumours originated from 36 males and 25 females, aged 54-83 years. Pure squamous cell differentiation (CK5/6 positive only) occurred in 34.4% (n=21) tumours and pure adenocarcinoma cell differentiation (CEA positive only) was present in 14.9% (n=9). Tumours with both squamous and adenocarcinoma features (CK5/6 and CEA positive) were most prevalent (47.5%, n=29). Two tumours (3.3%) were negative with both stains (and also synaptophysin negative). Double immunostaining (p63/CEA) revealed that squamous and adenocarcinoma markers were co-localised in cells in certain tumours. Conclusion: Co-localisation of squamous and adenocarcinoma markers in the same tumour cell suggests that additional analyses for novel biomarkers of specific lung cancer types may subsequently lead to a refined treatment choice for patients with the goal of improving clinical outcomes.
机译:目的:精确分类肺癌术对选择适当和充足的化疗治疗至关重要。在该研究中,在非小细胞肺癌(NSCLC)中检查腺(腺癌)和鳞状细胞分化,而无明显的鳞状和腺状分化的明显光显微镜迹象。材料和方法:通过支气管活检或由计算机断层扫描支撑的支气管活检或核心活组织检查获得,诊断为NSCLC(n = 61)的所有肺肿瘤。他们于1996 - 2009年诊断出来,在瑞典的Gavle Hospital省病理处。用针对CK5 / 6,P63(鳞状细胞标记物)和癌胚抗原(CEA)(腺癌细胞标记物)的抗体检查免疫组织化学。还对单个肿瘤进行双免疫染色(P63 / CEA)。结果:肿瘤起源于36名男性和25名女性,54-83岁。纯鳞状细胞分化(仅限CK5 / 6阳性)在34.4%(n = 21)肿瘤中发生,纯腺癌细胞分化(仅限CEA阳性)以14.9%(n = 9)存在。鳞状和腺癌特征(CK5 / 6和CEA阳性)的肿瘤最普遍(47.5%,N = 29)。两种肿瘤(3.3%)与污渍(以及突起的蛋白负阴性)为阴性。双重免疫染色(P63 / CEA)显示,鳞状和腺癌标记在某些肿瘤中的细胞中均为细胞。结论:同一肿瘤细胞中鳞状和腺癌标志物的共定位表明,特异性肺癌类型的新型生物标志物的额外分析可随后导致患者改善临床结果的精制治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号